FOGHORN THERAPEUTICS INC (FHTX) Fundamental Analysis & Valuation

NASDAQ:FHTX • US3441741077

Current stock price

5.09 USD
+0.09 (+1.8%)
At close:
5.09 USD
0 (0%)
After Hours:

This FHTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. FHTX Profitability Analysis

1.1 Basic Checks

  • FHTX had negative earnings in the past year.
  • FHTX had a negative operating cash flow in the past year.
  • FHTX had negative earnings in each of the past 5 years.
  • In the past 5 years FHTX reported 4 times negative operating cash flow.
FHTX Yearly Net Income VS EBIT VS OCF VS FCFFHTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

1.2 Ratios

  • FHTX has a Return On Assets of -37.50%. This is in the better half of the industry: FHTX outperforms 60.12% of its industry peers.
Industry RankSector Rank
ROA -37.5%
ROE N/A
ROIC N/A
ROA(3y)-34.14%
ROA(5y)-29.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FHTX Yearly ROA, ROE, ROICFHTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 -20K -40K -60K -80K -100K

1.3 Margins

  • FHTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FHTX Yearly Profit, Operating, Gross MarginsFHTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. FHTX Health Analysis

2.1 Basic Checks

  • FHTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for FHTX has been increased compared to 1 year ago.
  • Compared to 5 years ago, FHTX has more shares outstanding
  • FHTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
FHTX Yearly Shares OutstandingFHTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
FHTX Yearly Total Debt VS Total AssetsFHTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • FHTX has an Altman-Z score of -4.48. This is a bad value and indicates that FHTX is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of FHTX (-4.48) is worse than 61.08% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.48
ROIC/WACCN/A
WACC9.32%
FHTX Yearly LT Debt VS Equity VS FCFFHTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

2.3 Liquidity

  • FHTX has a Current Ratio of 2.73. This indicates that FHTX is financially healthy and has no problem in meeting its short term obligations.
  • FHTX has a worse Current ratio (2.73) than 68.02% of its industry peers.
  • A Quick Ratio of 2.73 indicates that FHTX has no problem at all paying its short term obligations.
  • The Quick ratio of FHTX (2.73) is worse than 65.13% of its industry peers.
Industry RankSector Rank
Current Ratio 2.73
Quick Ratio 2.73
FHTX Yearly Current Assets VS Current LiabilitesFHTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. FHTX Growth Analysis

3.1 Past

  • FHTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.09%, which is quite impressive.
  • The Revenue has grown by 36.75% in the past year. This is a very strong growth!
  • FHTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 135.14% yearly.
EPS 1Y (TTM)29.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.33%
Revenue 1Y (TTM)36.75%
Revenue growth 3Y17.14%
Revenue growth 5Y135.14%
Sales Q2Q%223.77%

3.2 Future

  • FHTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.46% yearly.
  • FHTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.52% yearly.
EPS Next Y8.27%
EPS Next 2Y2.21%
EPS Next 3Y9.36%
EPS Next 5Y15.46%
Revenue Next Year13.42%
Revenue Next 2Y14.23%
Revenue Next 3Y12.54%
Revenue Next 5Y31.52%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
FHTX Yearly Revenue VS EstimatesFHTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
FHTX Yearly EPS VS EstimatesFHTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. FHTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FHTX. In the last year negative earnings were reported.
  • Also next year FHTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FHTX Price Earnings VS Forward Price EarningsFHTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FHTX Per share dataFHTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.21%
EPS Next 3Y9.36%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FHTX Dividend Analysis

5.1 Amount

  • No dividends for FHTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FHTX Fundamentals: All Metrics, Ratios and Statistics

FOGHORN THERAPEUTICS INC

NASDAQ:FHTX (3/23/2026, 8:00:01 PM)

After market: 5.09 0 (0%)

5.09

+0.09 (+1.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-11
Earnings (Next)05-12
Inst Owners71.71%
Inst Owner Change1.83%
Ins Owners7.55%
Ins Owner Change0%
Market Cap298.78M
Revenue(TTM)30.91M
Net Income(TTM)-74.28M
Analysts87.5
Price Target11.56 (127.11%)
Short Float %2.57%
Short Ratio6.8
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.18%
Min EPS beat(2)-34.73%
Max EPS beat(2)26.37%
EPS beat(4)3
Avg EPS beat(4)7.28%
Min EPS beat(4)-34.73%
Max EPS beat(4)26.37%
EPS beat(8)7
Avg EPS beat(8)13.94%
EPS beat(12)11
Avg EPS beat(12)16.81%
EPS beat(16)12
Avg EPS beat(16)10.19%
Revenue beat(2)1
Avg Revenue beat(2)12.21%
Min Revenue beat(2)-4.57%
Max Revenue beat(2)28.98%
Revenue beat(4)3
Avg Revenue beat(4)9.69%
Min Revenue beat(4)-4.57%
Max Revenue beat(4)28.98%
Revenue beat(8)5
Avg Revenue beat(8)-2.36%
Revenue beat(12)8
Avg Revenue beat(12)22.8%
Revenue beat(16)8
Avg Revenue beat(16)5.54%
PT rev (1m)0%
PT rev (3m)-3.25%
EPS NQ rev (1m)3.46%
EPS NQ rev (3m)5.53%
EPS NY rev (1m)0.28%
EPS NY rev (3m)8.54%
Revenue NQ rev (1m)9.56%
Revenue NQ rev (3m)9.63%
Revenue NY rev (1m)1.35%
Revenue NY rev (3m)10.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.67
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.17
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0.53
BVpS-1.85
TBVpS-1.85
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -37.5%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.14%
ROA(5y)-29.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.5%
Cap/Sales 0.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.73
Quick Ratio 2.73
Altman-Z -4.48
F-Score3
WACC9.32%
ROIC/WACCN/A
Cap/Depr(3y)22%
Cap/Depr(5y)41.1%
Cap/Sales(3y)2.58%
Cap/Sales(5y)52.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.33%
EPS Next Y8.27%
EPS Next 2Y2.21%
EPS Next 3Y9.36%
EPS Next 5Y15.46%
Revenue 1Y (TTM)36.75%
Revenue growth 3Y17.14%
Revenue growth 5Y135.14%
Sales Q2Q%223.77%
Revenue Next Year13.42%
Revenue Next 2Y14.23%
Revenue Next 3Y12.54%
Revenue Next 5Y31.52%
EBIT growth 1Y18.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28.42%
EBIT Next 3YN/A
EBIT Next 5Y-10.3%
FCF growth 1Y14.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.25%
OCF growth 3YN/A
OCF growth 5YN/A

FOGHORN THERAPEUTICS INC / FHTX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for FOGHORN THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to FHTX.


Can you provide the valuation status for FOGHORN THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to FOGHORN THERAPEUTICS INC (FHTX). This can be considered as Overvalued.


What is the profitability of FHTX stock?

FOGHORN THERAPEUTICS INC (FHTX) has a profitability rating of 1 / 10.


Can you provide the financial health for FHTX stock?

The financial health rating of FOGHORN THERAPEUTICS INC (FHTX) is 2 / 10.